Sutro Biopharma
STRO
60 hedge funds and large institutions have $121M invested in Sutro Biopharma in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 29 increasing their positions, 15 reducing their positions, and 5 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 15
0.11% more ownership
Funds ownership: 5.03% → 5.14% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less capital invested
Capital invested by funds: $128M → $121M (-$6.76M)
6% less funds holding
Funds holding: 64 → 60 (-4)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.2M |
| 2 |
Barclays
London,
United Kingdom
|
+$2.22M |
| 3 |
Janus Henderson Group
London,
|
+$1.49M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$1.37M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$851K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VV Manager
Boston,
Massachusetts
|
-$5.58M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.89M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$655K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$629K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$424K |
STRO Hedge Fund Activity: Q1 2020 in Review
60 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2020, worth a combined $121M — down 5.3% from $128M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of STRO and 2 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 29 added.
The largest buyer was Adage Capital Partners, adding an estimated $4.2M. The largest seller was VV Manager, cutting an estimated $5.58M.
- 60 institutional investors held Sutro Biopharma (STRO) as of Q1 2020, down from 64 in Q4 2019.
- Funds reported $121M of Sutro Biopharma stock for Q1 2020, down 5.3% quarter-over-quarter.
- 2 funds opened new Sutro Biopharma positions in Q1 2020 and 5 closed out, a net change of -3 holders.
- The largest Sutro Biopharma buyer in Q1 2020 was Adage Capital Partners, an estimated $4.2M added.
- The largest Sutro Biopharma seller in Q1 2020 was VV Manager, an estimated $5.58M sold.
Based on aggregated 13F filings for Q1 2020.